Skip to main content

Table 2 Description of the characteristics of the 100 rheumatoid arthritis (RA) patients

From: Adherence to a treat-to-target strategy in early rheumatoid arthritis: results of the DREAM remission induction cohort

Age, mean ± SD years 57.7 ± 15.4
Female sex, n (%) 61 (61.0)
Symptom duration, median (IQR) weeks 12.0 (8.0 to 25.0)
Fulfillment of ACR 1987 criteria for RA, n (%) 81/97 (83.5)
RF positive, n (%) 61 (61.0)
Anti-CCP positive, n (%) 58/98 (59.2)
DAS28, mean ± SD 4.9 ± 1.1
No. of swollen joints (28 assessed), median (IQR) 7.0 (4.0 to 12.0)
No. of tender joints (28 assessed), median (IQR) 4.0 (2.0 to 10.0)
ESR, median (IQR) mm/hour 31.2 ± 18.5
CRP, median (IQR) mg/litre 11.5 (5.0 to 30.8)
Patient's assessment of general health, mean ± SD (0 to 100 VAS) 54.0 ± 22.5
Patient's assessment of pain, mean ± SD (0 to 100 VAS) 51.7 ± 23.0
HAQ score, mean ± SD 0.9 ± 0.7
SF-36 PCS score, mean ± SD 38.3 ± 10.0
SF-36 MCS score, mean ± SD 47.8 ± 12.6
  1. ACR, American College of Rheumatology; anti-CCP, anti-cyclic citrullinated peptide; CRP, C-reactive protein; DAS28, Disease Activity Score in 28 joints; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire; IQR, interquartile range; MCS, mental component summary; PCS, physical component summary; RF, rheumatoid factor; SD, standard deviation; SF-36, Short-Form 36 health survey; VAS, visual analog scale